晚期非小细胞肺癌双途径疗法临床研究  

A Clinical Study on the Double Pathway for Advanced Non-small-cell Lung Cancer

作　　者：赵军[1] 张丽华[1] 周玉芳[1] 司海运[1] 

机构地区：[1]聊城市人民医院肿瘤科,山东聊城252000

出　　处：《河南肿瘤学杂志》2004年第2期107-108,共2页Henan Journal of Oncology

摘　　要：目的　研究静脉全身化疗与局部免疫注射治疗相结合治疗非小细胞肺癌 (NSCLC)的疗效和毒副反应。方法　A组采用CAP、MVP方案交替化疗与局部免疫注射治疗相结合的双途径疗法 ,B组单纯应用上述两方案交替化疗。结果　A组近期有效率为67.65 % ,B组为 41.94% ,经统计学处理两组间有显著差异 (P <0 .0 5 ) ,而毒副反应两组间无明显差异 (P >0 .0 5 )。结论　上述双途径治疗法可作为晚期非小细胞肺癌安全有效的治疗方法。Objective To observe the effect and toxicity of intratumoral immunotherapy combining with chemotherapy.Methods The A group patients were given intratumoral immunotherapy combined with chemotherapy using CAP and MVP, respectively. The B group patients only received chemotherapy.Results The response rate was 67.65% in group A, 41.94% in group B. There was significant difference between the two groups (P<0.05). The side-effect with two groups was not different (P<0.05).Conclusions The double pathway was effective and safe in the treatment of advanced NSCLC patients.

关 键 词：晚期非小细胞肺癌 双途径疗法 局部免疫注射疗法 静脉全身化疗 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤] R730.5[医药卫生—临床医学]